Astec Lifesciences Ltd.

NSE: ASTEC BSE: 533138 SECTOR: Pesticides & Agrochemicals  39k   346   20

1463.90
+55.15 (3.91%)
NSE: Today, 03:52 PM

Price Summary

Today's High

₹ 1538.7

Today's Low

₹ 1415.05

52 Week High

₹ 2288.8

52 Week Low

₹ 1045

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

2870.07 Cr.

Enterprise Value

3147.63 Cr.

No. of Shares

1.96 Cr.

P/E

112.47

P/B

6.85

Face Value

₹ 10

Div. Yield

0.1 %

Book Value (TTM)

₹  213.61

CASH

1.81 Cr.

DEBT

279.37 Cr.

Promoter Holding

66.77 %

EPS (TTM)

₹  13.02

Sales Growth

21.93%

ROE

25.52 %

ROCE

22.22%

Profit Growth

38.84 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year21.93%
3 Year16.23%
5 Year16.69%

Profit Growth

1 Year38.84%
3 Year36.03%
5 Year36.3%

ROE%

1 Year25.52%
3 Year23.36%
5 Year22.44%

ROCE %

1 Year22.22%
3 Year21.63%
5 Year21.78%

Debt/Equity

0.706

Price to Cash Flow

122.59

Interest Cover Ratio

14.3155266110757

CFO/PAT (5 Yr. Avg.)

0.968044947314986

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2023 66.77 0
Dec 2022 66.77 0
Sep 2022 66.77 0
Jun 2022 65.29 0
Mar 2022 65.29 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 16.2278462249896% for the Past 3 years.
  • Company has been maintaining healthy ROE of 23.3625707307056% over the past 3 years.
  • Company has been maintaining healthy ROCE of 21.6267201808807% over the past 3 years.
  • Company has a healthy Interest coverage ratio of 14.3155266110757.
  • The company has an efficient Cash Conversion Cycle of 51.8262479115935 days.
  • The company has a high promoter holding of 66.77%.

 Limitations

  • Company has contingent liabilities of 244.4074 Cr.
  • The company is trading at a high EV/EBITDA of 35.1787.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
Net Sales 271.98 184.27 199.75 117.18 126.97
Total Expenditure 206.52 158.81 166.47 105.05 121.57
Operating Profit 65.46 25.45 33.28 12.13 5.4
Other Income 6.8 2.71 3.98 3.78 2.57
Interest 3.33 3.93 4.52 5.88 6.41
Depreciation 10.66 8.94 8.18 8.81 7.78
Exceptional Items 0 0 0 0 0
Profit Before Tax 58.28 15.29 24.56 1.21 -6.21
Tax 15.24 3.9 6.26 0.39 -1.22
Profit After Tax 43.04 11.39 18.3 0.83 -5
Adjusted EPS (Rs) 21.96 5.81 9.33 0.42 -2.55

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 370.85 430.9 522.22 554.87 676.57
Total Expenditure 302.09 354.49 437.02 443.47 522.73
Operating Profit 68.75 76.41 85.2 111.4 153.84
Other Income 8.11 11.1 11.93 7.78 10.71
Interest 10.66 12.38 12.64 4.79 9.09
Depreciation 14.67 19.34 23.22 25.71 34.42
Exceptional Items 4.15 0 0 0 0
Profit Before Tax 55.68 55.79 61.27 88.67 121.04
Tax 20.71 20.11 13.8 23.98 31.22
Net Profit 34.97 35.69 47.47 64.69 89.82
Adjusted EPS (Rs.) 17.91 18.25 24.26 33.03 45.83

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 19.53 19.55 19.57 19.59 19.6
Total Reserves 150.16 182.91 226.87 289.12 376.38
Borrowings 0.25 0 0 40 0
Other N/C liabilities 4.6 9.46 6.78 6.23 9.66
Current liabilities 238.6 249.16 318.88 322.97 491.07
Total Liabilities 413.14 461.09 572.1 677.9 896.71
Assets
Net Block 114.76 166.64 193.68 212.67 339.88
Capital WIP 41.78 18.63 22.11 111.68 13.73
Intangible WIP 0.09 0.35 2 4.04 9.09
Investments 0.49 0.49 0.49 0.43 0.43
Loans & Advances 24.46 26.57 22.13 18.66 18.2
Other N/C Assets 0 0 0 0 0
Current Assets 231.56 248.4 331.69 330.43 515.38
Total Assets 413.14 461.09 572.1 677.9 896.71
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 55.68 55.79 61.27 88.67 121.04
Adjustment 17.94 30.33 37.57 29.52 41.83
Changes in Assets & Liabilities 6.38 -54.4 87.92 -103.26 -110.33
Tax Paid -15.31 -16.41 -18.2 -22.99 -29.13
Operating Cash Flow 64.69 15.33 168.56 -8.06 23.41
Investing Cash Flow -48.94 -52.5 -73.81 -73.11 -103.57
Financing Cash Flow -18.24 37.09 -94.64 81.23 80.37
Net Cash Flow -2.49 -0.08 0.11 0.06 0.22

Corporate Actions

Investors Details

PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Promoters 65.29 65.29 66.77 66.77 66.77
godrej agrovet lim... 57.39 57.39 57.39 57.38 57.12
ashok vishwanath h... 9.92 9.95 9.95 9.95 9.96
chitralekha ashok ... - - - - -
PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Investors 34.71 34.71 33.23 33.23 33.23
shreans daga 2.92 2.92 2.92 2.92 2.92
sundaram mutual fu... - 2.05 2.05 2.05 -
sundaram mutual fu... 2.05 - - - 1.71
kaushik daga 2.04 2.04 2.04 - -
kaushik daga - - - 2.04 2.04
own infracon priva... - - - - -
own leasing and fi... - 1.31 1.32 - 1.31
own leasing and fi... 1.31 - - 1.32 -
vinodkumar harakch... - - - - -
kedia securities p... 1.02 1.02 - 1.02 1.02
iepf - 0.01 0.01 0.03 -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Astec Lifesciences - Quaterly Results2 May 2023, 5:51PM Astec Lifesciences - Quaterly Results2 May 2023, 5:51PM Astec Lifesciences - Quaterly Results2 May 2023, 5:51PM Astec LifeSciences launches R&D Center in Rabale11 Apr 2023, 2:58PM Astec Lifesciences gets nod to raise Rs 50 crore via NCDs 31 Jan 2023, 12:59PM Astec Lifesciences - Quaterly Results30 Jan 2023, 5:10PM Astec Lifesciences - Quaterly Results30 Jan 2023, 5:10PM Astec Lifesciences - Quaterly Results30 Jan 2023, 5:10PM Astec Lifesciences informs about outcome of board meeting29 Oct 2022, 11:49AM Astec Lifesciences - Quaterly Results28 Oct 2022, 4:37PM Astec Lifesciences - Quaterly Results28 Oct 2022, 4:37PM Astec Lifesciences - Quaterly Results28 Oct 2022, 4:37PM Astec Lifesciences informs about disclosure14 Oct 2022, 5:08PM Astec LifeSciences submits newspaper advertisement17 Aug 2022, 4:53PM Astec Lifesciences informs about postal ballot notice17 Aug 2022, 12:28PM Astec Lifesciences - Quaterly Results25 Jul 2022, 3:48PM Astec Lifesciences - Quaterly Results25 Jul 2022, 3:48PM Astec Lifesciences - Quaterly Results25 Jul 2022, 3:48PM Astec LifeSciences informs about disclosure of related party transactions14 Jun 2022, 3:21PM Astec Lifesciences - Quaterly Results2 May 2022, 5:13PM Astec Lifesciences - Quaterly Results2 May 2022, 5:13PM Astec Lifesciences - Quaterly Results2 May 2022, 5:13PM Astec Lifesciences informs about disclosure29 Mar 2022, 4:11PM Astec LifeSciences informs about board meeting18 Jan 2022, 4:32PM Astec LifeSciences informs about conference call27 Jul 2021, 12:16PM Astec LifeSciences informs about 28th AGM2 Jul 2021, 4:25PM Astec Lifesciences informs about trading window closure31 Dec 2020, 4:23PM Astec LifeSciences informs about disclosure19 Sep 2020, 11:12AM Astec Lifesciences sells entire equity stake in Astec Europe Sprl1 Sep 2020, 10:50AM Astec Lifesciences informs about clarification on price movements26 Jun 2020, 10:31AM Astec LifeSciences informs about analsyt meet18 May 2020, 11:19AM

Astec Lifesciences Stock Price Analysis and Quick Research Report. Is Astec Lifesciences an attractive stock to invest in?

 

Stock investing requires careful analysis of financial data to find out the company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement. This can be time-consuming and cumbersome. An easier way to find out about a company's performance is to look at its financial ratios, which can help to make sense of the overwhelming amount of information that can be found in a company's financial statements.

Here are the few indispensable tools that should be a part of every investor’s research process.

  • PE ratio: - Price to Earnings' ratio, which indicates for every rupee of earnings how much an investor is willing to pay for a share. A general rule of thumb is that shares trading at a LOW P/E are undervalued (it depends on other factors too). Astec Lifesciences has a PE ratio of 112.468404514409 which is high and comparatively overvalued .

  • Return on Assets (ROA): - Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Astec Lifesciences has ROA of 11.4083040636034 % which is a bad sign for future performance. (higher values are always desirable)

  • Current ratio: - The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Astec Lifesciences has a Current ratio of 1.04950601304591 .

  • Return on equity: - ROE measures the ability of a firm to generate profits from its shareholders investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Astec Lifesciences has a ROE of 25.5173290585694 % .(higher is better)

  • Debt to equity ratio: - It is a good metric to check out the capital structure along with its performance. Astec Lifesciences has a D/E ratio of 0.706 which means that the company has low proportion of debt in its capital.

  • Inventory turnover ratio: - Inventory Turnover ratio is an activity ratio and is a tool to evaluate the liquidity of a company's inventory. It measures how many times a company has sold and replaced its inventory during a certain period of time. Astec Lifesciences has an Inventory turnover ratio of 4.6398824179398 which shows that the management is inefficient in relation to its Inventory and working capital management.

  • Sales growth: - Astec Lifesciences has reported revenue growth of 21.9319010633261 % which is fair in relation to its growth and performance.

  • Operating Margin: - This will tell you about the operational efficiency of the company. The operating margin of Astec Lifesciences for the current financial year is 22.7377191969861 %.

  • Dividend Yield: - It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Astec Lifesciences is Rs 1.5 and the yield is 0.1012 %.

Brief about Astec Lifesciences

X